The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Replimune ...
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
Hosted on MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays
・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...
Hosted on MSN
REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?
・REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma. ・HOTH declined after a $2 million stock offering, along with ...
Integrations with Amazon Bedrock AgentCore, SageMaker and Quick aim to help Middle East enterprises operationalise agentic AI across hybrid and multi-cloud environments with trusted, real-time data ...
Access detailed historical stock prices, including daily closing prices, for REPL. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results